Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
Autoimmune disorders are frequent in chronic lymphocytic leukemia (CLL). Some drugs such as fludarabine may increase the risk of these phenomena and may even be fatal. The management of autoimmune disorders is not standard and corticosteroid is the most frequently used drug in these situations. Here, a case with CLL and severe autoimmune hemolytic anemia associated with fludarabine and successful treatment by rituximab has been reported.
Paydas
Semra
S
Department of Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey. sepay@cu.edu.tr
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000188:drug therapy* / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001803:Blood Transfusion; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014740:Vidarabine; C024352:fludarabine